ゾリンガー・エリソン症候群におけるウロガストロンの作用
Lancet (London, England)
|September 6, 1975
まとめ
ヒューマンウロガストロンは,ゾリンガー・エリソン症候群 (ZES) を効果的に治療します. この研究は,ウロガストロンがZES患者の胃酸と痛みを軽減することを示し,酸過分分泌状態に対する潜在的な治療アプローチを提供している.
科学分野:
- 胃腸内科 胃腸内科
- エンドクリノロジー エンドクリノロジー
- 薬理学 薬理学とは
背景:
- ゾリンガー・エリソン症候群 (Zollinger-Ellison syndrome,ZES) は,胃酸の過剰分泌によって特徴づけられる.
- ZESにおける酸過分分泌は,潰瘍や痛みを含む重度の胃腸疾患につながる.
- 現在の治療法は酸のレベルを管理することを目的としていますが,新しい治療薬は絶えず求められています.
研究 の 目的:
- ヒトウロガストロンの胃酸分泌と関連するパラメータに対するヒトウロガストロンの影響を,ゾリンガー・エリソン症候群の患者で調査する.
- ウロガストロンが胃酸量,濃度,内在因子,ペプシン,およびプラズマのガストリン濃度に与える影響を評価する.
- ZESに関連した潰瘍の痛みを緩和するウロガストロンの治療の可能性を評価する.
主な方法:
- ZESと診断された4人の男性患者と4人の健康な対照群に,ヒトウロガストロンの静脈内投与 (0-25mg/kg/時間) を行いました.
- 胃酸の量,濃度,固有因子,ペプシン,およびプラズマのガストリンのレベルを,ウロガストロン注入前および投与中に測定する.
- プラズマのガストリン濃度の変化と胃酸排出量の減少との相関分析.
主要な成果:
- ウロガストロンは,ZES患者における胃酸の量と濃度を著しく低下させ,基礎酸の排出量を50~82%減少させた.
- 胃ジュースの内因子とペプシン濃度は,ウロガストロン注入中に60~300%増加した.
- プラズマガストリンのピーク濃度は127-164%増加し,ガストリンの増加と酸の排出量の減少との間に有意な負の相関が観察されました (r=-0.72,P<0.01).
- 潰瘍の痛み緩和は,ウロガストロン注入を開始してから30〜60分以内に報告されました.
結論:
- ヒトのウロガストロンは,Zollinger-Ellison症候群における内在的に刺激された酸性高分泌の強力な阻害を示しています.
- ウロガストロンは,ZESおよび関連する酸性過分分泌障害の管理のための新しい治療戦略を提供することができる.
- プラズマのガストリンの増加は,複雑なフィードバックメカニズムまたはウロガストロンがガストリンの放出に直接作用することを示唆しています.
関連する概念動画
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
01:17Gastritis-II: Pathophysiology
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:30Peptic Ulcer Disease I: Introduction
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:26Gastritis II: Pathophysiology
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...